Covid and MS Part 7

What You Need to Know About COVID-19 and MS – Program 7

Featuring Barry Hendin, MD and Carrie Hersh, DO, MSc Recorded on October 19, 2020, this seventh installment of our ongoing webinar series provides the latest news and updates at the time of broadcast on the coronavirus (COVID-19) pandemic and its impact on multiple sclerosis. During this one-hour program, MSAA’s Chief Medical Officer Barry Hendin, MD […]

Read News Article
Losing Connection

Losing Connection: Difficult Discussions in a Virtual World

Featuring Mitzi Joi Williams, MD, Gavin Giovannoni, MBBCh, PhD, FCP, and Patient Advocate, Stanca Presented by two leading MS expert neurologists along with an MS patient advocate, this archived digital educational program features the best strategies for communicating in a virtual world. Explore how to best communicate difficult conversation topics with your MS healthcare professional […]

Read News Article

Vaccination Safety in MS – Download PDF

Yes, I’d like to receive email updates from MSAA! Please provide your email address and zip code so we may alert you about MS-related news, events, and programs happening in your area. * First Name * Last Name * Email * ZIP/Postal Code * Anti-Spam    check box please   – or –   Skip […]

Read News Article

Ask the Doctor: Viruses and Antibodies

Dr. Barry A. Hendin By Dr. Barry A. Hendin MSAA’s Chief Medical Officer Q: There is a lot of talk about antibodies for COVID-19 after a person has already contracted the coronavirus. I’ve heard that the COVID-19 antibodies don’t stay in the body indefinitely. Why then do the JC virus antibodies stay with us indefinitely […]

Read News Article

The Effects of the Pandemic on Individuals with MS

By Miriam Franco, PsyD MSCS Psychotherapist and Psychoanalyst An esteemed member of MSAA’s Healthcare Advisory Council for many years, Dr. Miriam Franco is a psychotherapist and psychoanalyst who specializes in helping individuals cope with chronic illness. She has a private practice in the Philadelphia area. “In my practice, I have observed particular reactions to the […]

Read News Article

Research News

FDA Approves Kesimpta® (Ofatumumab) for Relapsing Forms of MS On August 20, 2020, Novartis announced that the United States Food and Drug Administration (FDA) approved Kesimpta® (ofatumumab) for adults with relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease. Kesimpta is a B-cell therapy, which binds to and […]

Read News Article